Trial Profile
Adding Maraviroc to the HAART Regimen of HIV-infected Patients Who Are Well Controlled, and the Effect on CD4 Lymphocyte Counts
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 18 Oct 2016 New trial record